Response of facial haemangioma to oral propranolol

BMJ Case Reports

Volumn , Issue , 2009, Pages

  Itani, Mohamad Hassan ^a   Fakih, Hadi ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Sheikh Ragheb Harb Hospital Pediatrics   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77549088349     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.01.2009.1476     Document Type: Article

References (6)

1. Herzog C. Benign vascular tumors. Nelson textbook of pediatrics. 18th edn. Philadelphia: Saunders Elsevier, 2007: 2156-7.
2. Morelli GJ. Vascular disorders. Nelson textbook of pediatrics. 18th edn. Philadelphia: Saunders Elsevier, 2007: 2667-74.
3. Musumeci ML, Schlecht K, Perrotta R, et al. Management of cutaneous hemangiomas in pediatric patients. Cutis 2008; 81: 315-22.
4. Léauté-Labrèze C, Hubiche T, Boralev i F. Propranolol for severe hemangiomas of inf ancy. N Engl J Med 2008; 358: 2649.
5. Gal P, Reed M. General medications. Nelson textbook of pediatrics. 18th edn. Philadelphia: Saunders Elsevier, 2007: 2992.
6. D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997; 67: 353-66. (Pubitemid 27509471)